Completing data — refresh the page later to see the latest
1448867-41-1COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1AGBSXNCBIWWLHD-FQEVSTJZSA-NSiremadlin is an orally bioavailable human double minute 2 homolog (HDM2) inhibitor with potential antineoplastic activity. Siremadlin inhibits the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited, which may result in the restoration of both p53 signaling and p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger protein and negative regulator of the p53 pathway, is often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival.
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
UsesSiremadlin is an oral biologic agent that is a selective inhibitor of the p53-MDM2 interaction and is being investigated for the treatment of patients with myeloid malignancies after showing single agent activity in preclinical studies. the safety profile of Siremadlin did not differ significantly between tumor types and treatment regimens.
1448867-41-1CHEMBL3653256